May 3, 2024 – Agilent Technologies Inc. has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system sets a gold standard for acquiring, analyzing, and reporting flow data across diverse domains—from basic research to drug discovery and therapy development.

The NovoCyte Opteon represents a significant leap forward in flow cytometry technology, with configurations ranging from three to five lasers and support for up to 73 high-quality detectors. It meets researchers’ needs for sophisticated, large-panel flow cytometry assays while maintaining the easy-to-use features of the NovoCyte portfolio.

Read (Download) the full Press Release.

April 8, 2024 – Vizgen, Inc. the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, unveils the MERSCOPE® Ultra Platform and MERFISH 2.0 chemistry. These powerful tools are uniquely suited to supporting basic and translational research and will be commercially available in the second half of the year.

With 3x increased imaging area and 2x speed, coupled with enhanced MERFISH sensitivity, MERSCOPE Ultra will offer greater sample flexibility and throughput, accelerating both human and translational research.

The MERSCOPE Ultra Platform is a powerful new high plex in situ spatial multiomic analysis system. The MERSCOPE Ultra features the optimum combined capabilities of imaging area and throughput in a spatial transcriptomics imaging platform. The platform is capable of processing 3 cm2 of tissue on a single slide and acquires images at more than double the speed of the MERSCOPE Platform. Engineered for high-performance and optimized for throughput, MERSCOPE Ultra provides researchers with an industry-leading combination of imageable area, speed, and data quality to accelerate discovery and maximize the biology measured from every sample. Further, the system is the only spatial platform to offer two different size flow cells enabling users to adjust reagent consumption based on area imaged.

Read (Download) the full Press Release.

Check out this concise, comprehensive and stimulating Pocket Guide, a SPECTRUM of essential tools which may facilitate your research projects, saving time and money.

Request your personal printed copy!

Alternatively you can view it online or download the pdf. 

With the launch this week of its new Tapestri platform, single-cell omics firm Mission Bio is looking to make further inroads into the clinical trial and drug development businesses.

The new system adds protein measurements to the company's traditional focus on single-cell DNA sequencing, allowing researchers to make DNA and protein measurements in a single experiment and in single cells.

The system uses BioLegend's TotalSeq antibodies, which are conjugated to oligonucleotides, allowing them to be read out via single-cell sequencing. The current version of the Tapestri platform is intended for analysis of cell surface proteins, which enables researchers to identify cell type and subtype, generating data analogous to that provided by flow cytometry.